RET-CCDC6 (PTC1)

CCDC6-RET · Variant type: fusion · Fusion partner: CCDC6 (PTC1)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Lenvatinib	100.0%	0.0%	97.74
2	Regorafenib	99.9%	0.1%	95.99
3	Nintedanib	99.8%	0.2%	90.23
4	Alectinib	99.6%	0.4%	95.49
5	Selpercatinib	99.5%	0.5%	96.72
6	Ponatinib	99.5%	0.5%	78.23
7	Tivozanib	99.5%	0.6%	92.42
8	Pralsetinib	99.3%	0.7%	93.43
9	Tenalisib	98.9%	1.1%	97.98
10	Entrectinib	98.7%	1.3%	93.69
11	Fedratinib	98.4%	1.6%	96.21
12	Alpelisib	98.2%	1.8%	97.22
13	Sorafenib	97.9%	2.1%	96.72
14	Gilteritinib	96.9%	3.1%	88.97
15	Brigatinib	96.4%	3.6%	82.96
16	Cabozantinib	95.9%	4.1%	92.73
17	Futibatinib	94.8%	5.2%	98.48
18	Erdafitinib	94.7%	5.3%	95.71
19	Sunitinib	94.3%	5.7%	91.73
20	Vandetanib	92.8%	7.2%	95.74
21	Repotrectinib	91.2%	8.8%	84.21
22	Axitinib	89.8%	10.2%	93.23
23	Ibrutinib	87.7%	12.3%	94.74
24	Ripretinib	86.0%	14.0%	92.95
25	Fostamatinib	84.5%	15.4%	96.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Lenvatinib	100.0%	—	—
Regorafenib	99.9%	—	—
Nintedanib	99.8%	—	—
Alectinib	99.6%	—	—
Selpercatinib	99.5%	—	—
Ponatinib	99.5%	—	—
Tivozanib	99.5%	—	—
Pralsetinib	99.3%	—	—
Tenalisib	98.9%	—	—
Entrectinib	98.7%	—	—
Fedratinib	98.4%	—	—
Alpelisib	98.2%	—	—
Sorafenib	97.9%	—	—
Gilteritinib	96.9%	—	—
Brigatinib	96.4%	—	—
Cabozantinib	95.9%	—	—
Futibatinib	94.8%	—	—
Erdafitinib	94.7%	—	—
Sunitinib	94.3%	—	—
Vandetanib	92.8%	—	—
Repotrectinib	91.2%	—	—
Axitinib	89.8%	—	—
Ibrutinib	87.7%	—	—
Ripretinib	86.0%	—	—
Fostamatinib	84.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.9ms